Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (NASDAQ: REVB) is a clinical-stage life sciences company developing Gemini, a proprietary PHAD®-based toll-like receptor 4 (TLR4) agonist designed to rebalance the innate immune response in acute and chronic inflammation-driven diseases. The REVB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow key scientific, clinical, regulatory, and corporate developments.
News about Revelation Biosciences frequently highlights progress across its Gemini programs for acute kidney injury (GEMINI-AKI), chronic kidney disease (GEMINI-CKD), prevention of post-surgical infection (GEMINI-PSI), and treatment of severe burn-related hyperinflammation (GEM-PBI). Updates include clinical milestones such as Phase 1 and Phase 1b data from the PRIME study in stage 3 and 4 CKD patients, where the company has reported safety, reductions in inflammatory activity, and restoration of normal cellular responses to stimuli.
Investors and observers can also find announcements about interactions with the U.S. Food and Drug Administration, including submission and acceptance of an end-of-phase 1 meeting package for Gemini in AKI, as well as manufacturing news such as the start of GMP production of Gemini and placebo to support later-stage randomized, double-blinded, placebo-controlled trials.
Beyond clinical and regulatory updates, the REVB news stream covers financial and corporate actions disclosed by the company, including warrant exercise inducement transactions, special meetings of stockholders to approve share issuances under Nasdaq rules, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Bookmark this page to monitor Revelation Biosciences’ ongoing disclosures about Gemini’s development, capital markets activity, and governance events.
Revelation Biosciences Inc. (NASDAQ: REVB) reported statistically significant preclinical results for REVTx-300, a potential therapy for acute and chronic kidney disease. In a validated model, treatment with REVTx-300 led to significant reductions in TGF-β and increases in anti-inflammatory markers IL-10, hepcidin, and NGAL. No significant inflammation markers increased, indicating a potential reduction in fibrosis. The company plans to publish these findings in 2023 and is preparing to initiate clinical studies. Positive results were previously reported on October 25, 2022, and November 18, 2022, regarding renal fibrosis reduction.
Revelation Biosciences Inc. (NASDAQ: REVB) announced a 1-for-35 reverse stock split effective February 1, 2023, after stockholder approval. This action aims to increase the per-share market price to comply with NASDAQ's minimum bid requirements. Consequently, the outstanding shares will decrease to approximately 672,460 shares. Additionally, stockholders approved raising the authorized common stock to 500,000,000 shares and ratified Baker Tilly US, LLP as independent public accountants. The reverse split does not change stockholder equity proportions or the par value of the common stock.
Revelation Biosciences Inc. (NASDAQ: REVB) announced a mandatory separation of its trading units on January 13, 2023. Following this, units will cease to trade on the Nasdaq Capital Market. Each unit, consisting of one common stock share and one warrant priced at $11.50, will convert automatically into shares and warrants. Post-separation, common stock and warrants will trade under the symbols 'REVB' and 'REVBW'. Revelation focuses on immunologic therapies for disease prevention and treatment, with several candidates in development, including REVTx-100, REVTx-200, and REVTx-300.
Revelation Biosciences Inc. (NASDAQ: REVB) announced successful exploratory biomarker analyses supporting the clinical development of REVTx-300 for chronic kidney disease (CKD) and acute kidney injury (AKI). A significant 57% reduction in new collagen deposition was observed in preclinical models, indicating a potential for new intellectual property. Plans include initiating a Phase 1a study in early 2023, followed by a Phase 1b study in patients undergoing cardiac surgery. The CEO emphasized the therapeutic potential of modulating the innate immune response for treating inflammatory diseases.
Revelation Biosciences Inc. (NASDAQ: REVB) reported its third quarter 2022 financial results, highlighting key corporate developments. The company completed a $5.0 million public offering and licensed innovative IP for REVTx-100 aimed at healthcare-associated infections. Notably, positive preclinical data for REVTx-300 in kidney-related conditions was announced. As of September 30, 2022, cash and cash equivalents rose to $6.2 million from $1.3 million in 2021. However, the company recorded a net loss of $1.2 million for Q3 2022, down from $3.0 million in Q3 2021, indicating improved financial performance.
Revelation Biosciences Inc. (NASDAQ: REVB) announced promising preclinical results for REVTx-300, demonstrating a significant reduction in renal cortical fibrosis in models of acute kidney injury (AKI) and chronic kidney disease (CKD). High-dose treatment achieved a reduction of 29.3% (p < 0.05). The company plans to initiate Phase 1 clinical studies in the first half of 2023 and explore additional models including NASH and myocarditis. The findings suggest potential therapeutic benefits for health conditions associated with inflammation.
Revelation Biosciences Inc. (NASDAQ: REVB) announced an exclusive worldwide license with Vanderbilt University to develop phosphorylated hexaacyl disaccharide (PHAD) aimed at treating and preventing infections. The agreement focuses on combatting infections related to surgery, severe burns, and antibiotic resistance. Relevant data reveals approximately 687,000 cases of acquired infections leading to 72,000 deaths annually. Preclinical studies indicate PHAD could enhance innate immune response, potentially shortening infection duration and severity. Revelation also plans to prosecute additional patent applications for further innovations.
Revelation Biosciences Inc. (NASDAQ: REVB) reported its Q2 2022 financial results and recent advances on August 15, 2022. The company raised $5 million through a public offering and continues to progress with innovative therapies targeting allergies and chronic diseases.
As of June 30, 2022, cash reserves reached $3.5 million, bolstered by financing activities. Despite a net loss of $1.8 million for Q2 2022, improved from $2.5 million in Q2 2021, clinical studies were key contributors to operational expenses. The company expects sufficient funds to sustain operations through June 2023.
Revelation Biosciences Inc. (NASDAQ: REVB) announced the closure of a public offering on July 28, 2022, involving 8,333,334 shares at $0.60 each, raising approximately $5 million. The offering included warrants for an equal number of shares, exercisable at the same price for five years. The funds will support the development of their key therapeutic candidates, including REVTx-99b, REVTx-200, and REVTx-300, alongside general corporate purposes.
Revelation Biosciences Inc. (NASDAQ: REVB) has announced a public offering of 8,333,334 shares of common stock, priced at $0.60 per share, along with warrants to purchase an equal number of shares. The offering aims to raise approximately $5 million before fees, and proceeds will be used for the development of product candidates REVTx-99b, REVTx-200, and REVTx-300, among other corporate purposes. The offering is expected to close on or about July 28, 2022.